Furthermore, ANXA5 administration in mice enhanced immunogenicity by binding to PS and inducing systemic cytotoxic T-cell responses, leading to tumor regression and reduced relapse (Li et al., 2020). This evidence concerns the gene ANXA5 and neoplasm.